{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:22:02Z","timestamp":1787757722629,"version":"build-2784847793"},"reference-count":63,"publisher":"American Association for Cancer Research (AACR)","issue":"8","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/TCR\/007-NCC\/2013"],"award-info":[{"award-number":["NMRC\/TCR\/007-NCC\/2013"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/CSA\/007\/2016"],"award-info":[{"award-number":["NMRC\/CSA\/007\/2016"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005923","name":"International Association for the Study of Lung Cancer","doi-asserted-by":"publisher","award":["Fellowship 2018"],"award-info":[{"award-number":["Fellowship 2018"]}],"id":[{"id":"10.13039\/100005923","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Despite widespread use of targeted therapies, little is known about how tumors and their microenvironment respond in the earliest phases of treatment and whether these early changes reveal new therapeutic opportunities. In this study, we investigated how short-term epidermal growth factor receptor (EGFR) inhibition reshapes tumor biology and the tumor microenvironment using comprehensive multiregion and spatial molecular profiling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and Methods:<\/jats:title>\n                    <jats:p>Patients with stage IA\u2013IIIA EGFR-mutated non\u2013small cell lung cancer (NSCLC) received at least 4 weeks of gefitinib (250 mg daily) before surgery. Multiregion whole-exome and RNA sequencing of resected tumors were compared with a purity-matched treatment-na\u00efve cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Thirteen patients received neoadjuvant gefitinib for a median of 1.4 months, achieving objective response and disease control rates of 62% and 100%, respectively. Pathologic downstaging occurred in 46% of patients, with major pathologic response in 8%. Deep genomic and transcriptomic profiling revealed rapid tumor and microenvironmental adaptation to EGFR inhibition without emergence of common acquired resistance mutations such as EGFR T790M. Compared with treatment-na\u00efve tumors, on-treatment tumors showed reduced tumor purity, decreased EGFR amplification, increased immunoregulatory and inflammatory gene expression, and a metabolic shift from glycolysis to oxidative phosphorylation, spatially validated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>These findings show that early EGFR inhibition triggers coordinated remodeling of tumor cells and the microenvironment, uncovering new therapeutic vulnerabilities and opening a window for rational combination strategies to improve outcomes in EGFR-mutated NSCLC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>This study demonstrated that neoadjuvant gefitinib is safe, feasible, and effective. Multiregion and spatial genomic and transcriptomic sequencing provided unique insight into adaptive response in the tumor and microenvironment. This window-of-opportunity study uncovered the potential for rational combination approaches to improve therapeutic efficacy in EGFR-mutated NSCLC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-26-0073","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T21:16:18Z","timestamp":1786482978000},"page":"1993-2009","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Early EGFR Inhibition Triggers Actionable Tumor and Microenvironmental Remodeling in Lung Cancer"],"prefix":"10.1158","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7292-1114","authenticated-orcid":false,"given":"Aaron C.","family":"Tan","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore 1 Division of Medical Oncology, , Singapore, Singapore."},{"id":[{"id":"https:\/\/ror.org\/02j1m6098","id-type":"ROR","asserted-by":"publisher"}],"name":"Duke-NUS Medical School 2 , National University of Singapore, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2626-6694","authenticated-orcid":false,"given":"Jia Chi","family":"Yeo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05k8wg936","id-type":"ROR","asserted-by":"publisher"}],"name":"Genome Institute of Singapore (GIS) 3 , Agency for Science, Technology and Research (A*STAR), Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7292-2982","authenticated-orcid":false,"given":"Jacob J.S.","family":"Alvarez","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05k8wg936","id-type":"ROR","asserted-by":"publisher"}],"name":"Genome Institute of Singapore (GIS) 3 , Agency for Science, Technology and Research (A*STAR), Singapore, Singapore."},{"name":"4Department of Computer Science, National University of Singapore, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2503-7550","authenticated-orcid":false,"given":"Mengyuan","family":"Pang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05k8wg936","id-type":"ROR","asserted-by":"publisher"}],"name":"Genome Institute of Singapore (GIS) 3 , Agency for Science, Technology and Research (A*STAR), Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3478-7991","authenticated-orcid":false,"given":"Yu Amanda","family":"Guo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05k8wg936","id-type":"ROR","asserted-by":"publisher"}],"name":"Genome Institute of Singapore (GIS) 3 , Agency for Science, Technology and Research (A*STAR), Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0295-9472","authenticated-orcid":false,"given":"Regina","family":"Hoo","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02j1m6098","id-type":"ROR","asserted-by":"publisher"}],"name":"Duke-NUS Medical School 5 Centre for Biomedical Data Science & Programme in Cancer & Stem Cell Biology, , National University of Singapore, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7830-8430","authenticated-orcid":false,"given":"Angela M.","family":"Takano","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/036j6sg82","id-type":"ROR","asserted-by":"publisher"}],"name":"Singapore General Hospital 6 Division of Pathology, , Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0782-3363","authenticated-orcid":false,"given":"Boon-Hean","family":"Ong","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04f8k9513","id-type":"ROR","asserted-by":"publisher"}],"name":"National Heart Centre Singapore 7 Department of Cardiothoracic Surgery, , Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4598-4181","authenticated-orcid":false,"given":"Denise","family":"Goh","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/04xpsrn94","id-type":"ROR","asserted-by":"publisher"}],"name":"Institute of Molecular and Cell Biology (IMCB) 8 , Agency for Science, Technology and Research (A*STAR), Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6674-7153","authenticated-orcid":false,"given":"Joe","family":"Yeong","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/036j6sg82","id-type":"ROR","asserted-by":"publisher"}],"name":"Singapore General Hospital 6 Division of Pathology, , Singapore, Singapore."},{"id":[{"id":"https:\/\/ror.org\/04xpsrn94","id-type":"ROR","asserted-by":"publisher"}],"name":"Institute of Molecular and Cell Biology (IMCB) 8 , Agency for Science, Technology and Research (A*STAR), Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9229-6176","authenticated-orcid":false,"given":"Zhengwei","family":"Wu","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05k8wg936","id-type":"ROR","asserted-by":"publisher"}],"name":"Genome Institute of Singapore (GIS) 3 , Agency for Science, Technology and Research (A*STAR), Singapore, Singapore."},{"name":"9Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3951-9411","authenticated-orcid":false,"given":"Ju","family":"Yuan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05k8wg936","id-type":"ROR","asserted-by":"publisher"}],"name":"Genome Institute of Singapore (GIS) 3 , Agency for Science, Technology and Research (A*STAR), Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7431-9119","authenticated-orcid":false,"given":"S.","family":"Shathishwaran","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05k8wg936","id-type":"ROR","asserted-by":"publisher"}],"name":"Genome Institute of Singapore (GIS) 3 , Agency for Science, Technology and Research (A*STAR), Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4211-035X","authenticated-orcid":false,"given":"Ngak Leng","family":"Sim","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05k8wg936","id-type":"ROR","asserted-by":"publisher"}],"name":"Genome Institute of Singapore (GIS) 3 , Agency for Science, Technology and Research (A*STAR), Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0083-0181","authenticated-orcid":false,"given":"Khi Pin","family":"Chua","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05k8wg936","id-type":"ROR","asserted-by":"publisher"}],"name":"Genome Institute of Singapore (GIS) 3 , Agency for Science, Technology and Research (A*STAR), Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2365-5264","authenticated-orcid":false,"given":"Wai Leong","family":"Tam","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05k8wg936","id-type":"ROR","asserted-by":"publisher"}],"name":"Genome Institute of Singapore (GIS) 3 , Agency for Science, Technology and Research (A*STAR), Singapore, Singapore."},{"name":"9Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore."},{"name":"10Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5414-0055","authenticated-orcid":false,"given":"Lan Ying","family":"Wang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore 1 Division of Medical Oncology, , Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7058-4994","authenticated-orcid":false,"given":"Dawn P.X","family":"Lau","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore 1 Division of Medical Oncology, , Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3520-9464","authenticated-orcid":false,"given":"Stephanie P.","family":"Saw","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore 1 Division of Medical Oncology, , Singapore, Singapore."},{"id":[{"id":"https:\/\/ror.org\/02j1m6098","id-type":"ROR","asserted-by":"publisher"}],"name":"Duke-NUS Medical School 2 , National University of Singapore, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3594-9374","authenticated-orcid":false,"given":"Amit","family":"Jain","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore 1 Division of Medical Oncology, , Singapore, Singapore."},{"id":[{"id":"https:\/\/ror.org\/02j1m6098","id-type":"ROR","asserted-by":"publisher"}],"name":"Duke-NUS Medical School 2 , National University of Singapore, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3586-2201","authenticated-orcid":false,"given":"Gillianne G.","family":"Lai","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore 1 Division of Medical Oncology, , Singapore, Singapore."},{"id":[{"id":"https:\/\/ror.org\/02j1m6098","id-type":"ROR","asserted-by":"publisher"}],"name":"Duke-NUS Medical School 2 , National University of Singapore, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1744-0008","authenticated-orcid":false,"given":"Wan Ling","family":"Tan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore 1 Division of Medical Oncology, , Singapore, Singapore."},{"id":[{"id":"https:\/\/ror.org\/02j1m6098","id-type":"ROR","asserted-by":"publisher"}],"name":"Duke-NUS Medical School 2 , National University of Singapore, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3209-864X","authenticated-orcid":false,"given":"Mei Kim","family":"Ang","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore 1 Division of Medical Oncology, , Singapore, Singapore."},{"id":[{"id":"https:\/\/ror.org\/02j1m6098","id-type":"ROR","asserted-by":"publisher"}],"name":"Duke-NUS Medical School 2 , National University of Singapore, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5815-6900","authenticated-orcid":false,"given":"Quan Sing","family":"Ng","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore 1 Division of Medical Oncology, , Singapore, Singapore."},{"id":[{"id":"https:\/\/ror.org\/02j1m6098","id-type":"ROR","asserted-by":"publisher"}],"name":"Duke-NUS Medical School 2 , National University of Singapore, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2351-881X","authenticated-orcid":false,"given":"Ravindran","family":"Kanesvaran","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore 1 Division of Medical Oncology, , Singapore, Singapore."},{"id":[{"id":"https:\/\/ror.org\/02j1m6098","id-type":"ROR","asserted-by":"publisher"}],"name":"Duke-NUS Medical School 2 , National University of Singapore, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4655-0206","authenticated-orcid":false,"given":"Darren W.","family":"Lim","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore 1 Division of Medical Oncology, , Singapore, Singapore."},{"id":[{"id":"https:\/\/ror.org\/02j1m6098","id-type":"ROR","asserted-by":"publisher"}],"name":"Duke-NUS Medical School 2 , National University of Singapore, Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6847-4980","authenticated-orcid":false,"given":"Anders J.","family":"Skanderup","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/05k8wg936","id-type":"ROR","asserted-by":"publisher"}],"name":"Genome Institute of Singapore (GIS) 3 , Agency for Science, Technology and Research (A*STAR), Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6514-6786","authenticated-orcid":false,"given":"Daniel S.","family":"Tan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03bqk3e80","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Centre Singapore 1 Division of Medical Oncology, , Singapore, Singapore."},{"id":[{"id":"https:\/\/ror.org\/02j1m6098","id-type":"ROR","asserted-by":"publisher"}],"name":"Duke-NUS Medical School 2 , National University of Singapore, Singapore, Singapore."},{"id":[{"id":"https:\/\/ror.org\/05k8wg936","id-type":"ROR","asserted-by":"publisher"}],"name":"Genome Institute of Singapore (GIS) 3 , Agency for Science, Technology and Research (A*STAR), Singapore, Singapore."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"2026082610504613200_bib1","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1200\/JCO.21.01626","article-title":"Targeted therapies for lung cancer patients with oncogenic driver molecular alterations","volume":"40","author":"Tan","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026082610504613200_bib2","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N Engl J Med"},{"issue":"Supplement 2","key":"2026082610504613200_bib3","doi-asserted-by":"publisher","first-page":"S1306","DOI":"10.1016\/j.annonc.2023.10.062","article-title":"LBA14 Amivantamab plus lazertinib vs osimertinib as first-line treatment in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC): primary results from MARIPOSA, a phase III, global, randomized, controlled trial","volume":"34","author":"Cho","year":"2023","journal-title":"Ann Oncol"},{"key":"2026082610504613200_bib4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1056\/NEJMoa2304594","article-title":"Overall survival with osimertinib in resected EGFR-mutated NSCLC","volume":"389","author":"Tsuboi","year":"2023","journal-title":"N Engl J Med"},{"key":"2026082610504613200_bib5","doi-asserted-by":"publisher","first-page":"e501","DOI":"10.1016\/S1470-2045(21)00383-1","article-title":"Revisiting neoadjuvant therapy in non-small-cell lung cancer","volume":"22","author":"Saw","year":"2021","journal-title":"Lancet Oncol"},{"key":"2026082610504613200_bib6","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"2026082610504613200_bib7","doi-asserted-by":"publisher","first-page":"6229","DOI":"10.1200\/JCO.2009.22.3370","article-title":"Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer","volume":"27","author":"Lara-Guerra","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026082610504613200_bib8","doi-asserted-by":"publisher","first-page":"2731","DOI":"10.1200\/JCO.2011.39.4882","article-title":"Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer","volume":"30","author":"Schaake","year":"2012","journal-title":"J Clin Oncol"},{"key":"2026082610504613200_bib9","doi-asserted-by":"publisher","first-page":"3105","DOI":"10.1200\/JCO.24.00071","article-title":"Neoadjuvant osimertinib for the treatment of stage I-IIIA epidermal growth factor receptor-mutated non-small cell lung cancer: a phase II multicenter study","volume":"42","author":"Blakely","year":"2024","journal-title":"J Clin Oncol"},{"key":"2026082610504613200_bib10","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41568-024-00737-z","article-title":"Cancer drug-tolerant persister cells: from biological questions to clinical opportunities","volume":"24","author":"Russo","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"2026082610504613200_bib11","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.jtho.2024.12.023","article-title":"Neoadjuvant and adjuvant osimertinib in stage IA to IIIA, EGFR-mutant NSCLC (NORA)","volume":"20","author":"Lee","year":"2025","journal-title":"J Thorac Oncol"},{"key":"2026082610504613200_bib12","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.1038\/s41467-024-47423-0","article-title":"Focal adhesion kinase-YAP signaling axis drives drug-tolerant persister cells and residual disease in lung cancer","volume":"15","author":"Haderk","year":"2024","journal-title":"Nat Commun"},{"key":"2026082610504613200_bib13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.celrep.2015.03.012","article-title":"NF-\u03baB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancer","volume":"11","author":"Blakely","year":"2015","journal-title":"Cell Rep"},{"key":"2026082610504613200_bib14","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"2026082610504613200_bib15","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41467-017-02584-z","article-title":"Elucidating the genomic architecture of Asian EGFR-mutant lung adenocarcinoma through multi-region exome sequencing","volume":"9","author":"Nahar","year":"2018","journal-title":"Nat Commun"},{"key":"2026082610504613200_bib16","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S1470-2045(13)70334-6","article-title":"Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint","volume":"15","author":"Hellmann","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026082610504613200_bib17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","article-title":"STAR: ultrafast universal RNA-seq aligner","volume":"29","author":"Dobin","year":"2013","journal-title":"Bioinformatics"},{"key":"2026082610504613200_bib18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"2026082610504613200_bib19","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"2026082610504613200_bib20","doi-asserted-by":"publisher","first-page":"R29","DOI":"10.1186\/gb-2014-15-2-r29","article-title":"voom: precision weights unlock linear model analysis tools for RNA-seq read counts","volume":"15","author":"Law","year":"2014","journal-title":"Genome Biol"},{"key":"2026082610504613200_bib21","doi-asserted-by":"publisher","first-page":"e2","DOI":"10.1093\/nar\/gkad1026","article-title":"standR: spatial transcriptomic analysis for GeoMx DSP data","volume":"52","author":"Liu","year":"2024","journal-title":"Nucleic Acids Res"},{"key":"2026082610504613200_bib22","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1038\/s41587-019-0114-2","article-title":"Determining cell type abundance and expression from bulk tissues with digital cytometry","volume":"37","author":"Newman","year":"2019","journal-title":"Nat Biotechnol"},{"key":"2026082610504613200_bib23","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"2026082610504613200_bib24","doi-asserted-by":"publisher","first-page":"5939","DOI":"10.1158\/1078-0432.CCR-20-4607","article-title":"Integrative profiling of T790M-negative EGFR-mutated NSCLC reveals pervasive lineage transition and therapeutic opportunities","volume":"27","author":"Chua","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2026082610504613200_bib25","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1158\/2643-3230.BCD-21-0092","article-title":"Reconstructing complex cancer evolutionary histories from multiple bulk DNA samples using pairtree","volume":"3","author":"Wintersinger","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"2026082610504613200_bib26","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41416-020-01048-4","article-title":"Cytotoxic CD8 T cells in cancer and cancer immunotherapy","volume":"124","author":"Raskov","year":"2021","journal-title":"Br J Cancer"},{"key":"2026082610504613200_bib27","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41573-022-00520-5","article-title":"Macrophages as tools and targets in cancer therapy","volume":"21","author":"Mantovani","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"2026082610504613200_bib28","doi-asserted-by":"publisher","first-page":"100070","DOI":"10.1016\/j.iotech.2022.100070","article-title":"CD47-SIRP\u03b1-targeted therapeutics: status and prospects","volume":"13","author":"Maute","year":"2022","journal-title":"Immunooncol Technol"},{"key":"2026082610504613200_bib29","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-3-030-35582-1_8","article-title":"CD200-CD200R pathway in the regulation of tumor immune microenvironment and immunotherapy","volume":"1223","author":"Liu","year":"2020","journal-title":"Adv Exp Med Biol"},{"key":"2026082610504613200_bib30","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.3390\/cancers12071765","article-title":"The CCL5\/CCR5 axis in cancer progression","volume":"12","author":"Aldinucci","year":"2020","journal-title":"Cancers"},{"key":"2026082610504613200_bib31","doi-asserted-by":"publisher","first-page":"574667","DOI":"10.3389\/fphar.2020.574667","article-title":"The role of the CXCL12\/CXCR4\/CXCR7 chemokine axis in cancer","volume":"11","author":"Shi","year":"2020","journal-title":"Front Pharmacol"},{"key":"2026082610504613200_bib32","doi-asserted-by":"publisher","first-page":"5975","DOI":"10.4049\/jimmunol.176.10.5975","article-title":"OX40-OX40 ligand interaction through T cell-T cell contact contributes to CD4 T cell longevity","volume":"176","author":"Soroosh","year":"2006","journal-title":"J Immunol"},{"key":"2026082610504613200_bib33","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nri1371","article-title":"Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40","volume":"4","author":"Sugamura","year":"2004","journal-title":"Nat Rev Immunol"},{"key":"2026082610504613200_bib34","doi-asserted-by":"publisher","first-page":"e1004321","DOI":"10.1371\/journal.pcbi.1004321","article-title":"Escher: a web application for building, sharing, and embedding data-rich visualizations of biological pathways","volume":"11","author":"King","year":"2015","journal-title":"PLoS Comput Biol"},{"key":"2026082610504613200_bib35","doi-asserted-by":"publisher","first-page":"1798","DOI":"10.1016\/j.jtho.2021.07.017","article-title":"Mechanism of drug tolerant persister cancer cells: the landscape and clinical implication for therapy","volume":"16","author":"Mikubo","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2026082610504613200_bib36","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.cell.2020.07.017","article-title":"Therapy-induced evolution of human lung cancer revealed by single-cell RNA sequencing","volume":"182","author":"Maynard","year":"2020","journal-title":"Cell"},{"key":"2026082610504613200_bib37","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/s41586-021-03796-6","article-title":"Cycling cancer persister cells arise from lineages with distinct programs","volume":"596","author":"Oren","year":"2021","journal-title":"Nature"},{"key":"2026082610504613200_bib38","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1056\/NEJMoa1716078","article-title":"Neoadjuvant PD-1 blockade in resectable lung cancer","volume":"378","author":"Forde","year":"2018","journal-title":"N Engl J Med"},{"key":"2026082610504613200_bib39","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.lungcan.2022.06.009","article-title":"Correlations between objective response rate and survival-based endpoints in first-line advanced non-small cell lung cancer: a systematic review and meta-analysis","volume":"170","author":"Goring","year":"2022","journal-title":"Lung Cancer"},{"key":"2026082610504613200_bib40","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1200\/JCO.2014.59.0489","article-title":"Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses","volume":"33","author":"Blumenthal","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026082610504613200_bib41","doi-asserted-by":"publisher","first-page":"100398","DOI":"10.1016\/j.esmoop.2022.100398","article-title":"Correlation between treatment effects on response rate and progression-free survival and overall survival in trials of targeted therapies in molecularly enriched populations","volume":"7","author":"Solomon","year":"2022","journal-title":"ESMO Open"},{"key":"2026082610504613200_bib42","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1093\/annonc\/mdx414","article-title":"Exploratory analysis of the association of depth of response and survival in patients with metastatic non-small-cell lung cancer treated with a targeted therapy or immunotherapy","volume":"28","author":"McCoach","year":"2017","journal-title":"Ann Oncol"},{"key":"2026082610504613200_bib43","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.jtcvs.2020.02.131","article-title":"Gefitinib as neoadjuvant therapy for resectable stage II-IIIA non-small cell lung cancer: a phase II study","volume":"161","author":"Zhang","year":"2021","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026082610504613200_bib44","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1200\/JCO.19.00075","article-title":"Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase II study","volume":"37","author":"Zhong","year":"2019","journal-title":"J Clin Oncol"},{"key":"2026082610504613200_bib45","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1634\/theoncologist.2018-0120","article-title":"Erlotinib as neoadjuvant therapy in stage IIIA (N2) EGFR mutation-positive non-small cell lung cancer: a prospective, single-arm, phase II study","volume":"24","author":"Xiong","year":"2019","journal-title":"Oncologist"},{"key":"2026082610504613200_bib46","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO-25-00883","article-title":"Neoadjuvant osimertinib for resectable EGFR-mutated non-small cell lung cancer","volume":"43","author":"He","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026082610504613200_bib47","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nm.4040","article-title":"Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition","volume":"22","author":"Hata","year":"2016","journal-title":"Nat Med"},{"key":"2026082610504613200_bib48","doi-asserted-by":"publisher","first-page":"2666","DOI":"10.3390\/cancers13112666","article-title":"Emerging insights into targeted therapy-tolerant persister cells in cancer","volume":"13","author":"Cabanos","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2026082610504613200_bib49","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41392-024-01891-4","article-title":"Drug tolerant persister cell plasticity in cancer: a revolutionary strategy for more effective anticancer therapies","volume":"9","author":"He","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"2026082610504613200_bib50","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1200\/JCO.19.01154","article-title":"Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer","volume":"38","author":"Noronha","year":"2020","journal-title":"J Clin Oncol"},{"key":"2026082610504613200_bib51","doi-asserted-by":"publisher","first-page":"3587","DOI":"10.1200\/JCO.21.02911","article-title":"Updated analysis of NEJ009: gefitinib-alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"40","author":"Miyauchi","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026082610504613200_bib52","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1158\/2159-8290.CD-13-0310","article-title":"Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors","volume":"3","author":"Akbay","year":"2013","journal-title":"Cancer Discov"},{"key":"2026082610504613200_bib53","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1158\/2326-6066.CIR-18-0193","article-title":"A high-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of antigen-specific cytotoxic T-lymphocyte tumor cell killing","volume":"6","author":"Lizotte","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"2026082610504613200_bib54","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/ijc.32191","article-title":"EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: implications for combination therapies","volume":"145","author":"Jia","year":"2019","journal-title":"Int J Cancer"},{"key":"2026082610504613200_bib55","doi-asserted-by":"publisher","first-page":"70","DOI":"10.4143\/crt.2023.482","article-title":"Tumor microenvironment modulation by neoadjuvant erlotinib therapy and its clinical impact on operable EGFR-mutant non-small cell lung cancer","volume":"56","author":"Ahn","year":"2024","journal-title":"Cancer Res Treat"},{"key":"2026082610504613200_bib56","doi-asserted-by":"publisher","first-page":"1209947","DOI":"10.3389\/fimmu.2023.1209947","article-title":"Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects","volume":"14","author":"Cheng","year":"2023","journal-title":"Front Immunol"},{"key":"2026082610504613200_bib57","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1186\/s40425-018-0368-0","article-title":"Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches","volume":"6","author":"Parra","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2026082610504613200_bib58","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jtho.2020.09.027","article-title":"Neoadjuvant chemotherapy increases cytotoxic T cell, tissue resident memory T cell, and B cell infiltration in resectable NSCLC","volume":"16","author":"Gaudreau","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2026082610504613200_bib59","doi-asserted-by":"publisher","first-page":"e192553","DOI":"10.1001\/jamaoncol.2019.2553","article-title":"Effect of metformin plus tyrosine kinase inhibitors compared with tyrosine kinase inhibitors alone in patients with epidermal growth factor receptor-mutated lung adenocarcinoma: a phase 2 randomized clinical trial","volume":"5","author":"Arrieta","year":"2019","journal-title":"JAMA Oncol"},{"key":"2026082610504613200_bib60","doi-asserted-by":"publisher","first-page":"6967","DOI":"10.1158\/1078-0432.CCR-19-0437","article-title":"Combination of metformin and gefitinib as first-line therapy for nondiabetic advanced NSCLC patients with EGFR mutations: a randomized, double-blind phase II trial","volume":"25","author":"Li","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2026082610504613200_bib61","doi-asserted-by":"publisher","first-page":"786","DOI":"10.3390\/ph15070786","article-title":"Will we unlock the benefit of metformin for patients with lung cancer? Lessons from current evidence and new hypotheses","volume":"15","author":"Barrios-Bernal","year":"2022","journal-title":"Pharmaceuticals (Basel)"},{"key":"2026082610504613200_bib62","doi-asserted-by":"publisher","first-page":"4045","DOI":"10.2217\/fon-2021-0549","article-title":"Neoadjuvant osimertinib with\/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA","volume":"17","author":"Tsuboi","year":"2021","journal-title":"Future Oncol"},{"key":"2026082610504613200_bib63","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1158\/0008-5472.CAN-23-2551","article-title":"Oncogene-driven non-small cell lung cancers in patients with a history of smoking lack smoking-induced mutations","volume":"84","author":"Huang","year":"2024","journal-title":"Cancer Res"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-26-0073\/3820875\/crc-26-0073.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/8\/1993\/3825297\/crc-26-0073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/6\/8\/1993\/3825297\/crc-26-0073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:50:55Z","timestamp":1787755855000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/6\/8\/1993\/787704\/Early-EGFR-Inhibition-Triggers-Actionable-Tumor"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":63,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-26-0073","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2767-9764.33341618","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341717","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341648","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341636","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341705","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341606","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341600","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341666","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341711","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341654","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341624","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341612","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341678","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341684","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341672","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341597","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341642","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341630","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341696","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341693","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341681","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341708","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341609","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341615","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341603","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341669","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341639","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341702","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341627","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341714","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341633","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341699","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341621","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341687","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341657","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341720","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341645","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341651","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341675","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341663","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341690","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.33341660","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.c.8675702","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}